Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study
Authors:
- George A. KarpouzasGKGeorge A. Karpouzas
- Sarah R. OrmsethSOSarah R. Ormseth
- Piet Van RielPRPiet Van Riel
- Elena MyasoedovaEMElena Myasoedova
- Miguel A. Gonzalez-GayMiguel A. Gonzalez-Gay
- Alfonso CorralesACAlfonso Corrales
- Solbritt Rantapaa-DahlqvistSRSolbritt Rantapaa-Dahlqvist
- Petros SfikakisPSPetros Sfikakis
- Patrick DesseinPDPatrick Dessein
- Carol A. HitchonCHCarol A. Hitchon
- Virginia Pascual-RamosVPVirginia Pascual-Ramos
- Irazu Contreras YanezIYIrazu Contreras Yanez
- 18 April 2025
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 45 (5) , 1-11
Abstract
Objective Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk. Methotrexate may decrease this risk, although it is unclear whether males and females similarly benefit. We explored the influence of sex on the effect of methotrexate use on cardiovascular risk in RA. Methods An observational cohort of 4362 patients, 3223 (73.9%) females, without cardiovascular disease were included from an international cardiovascular consortium for RA. Outcomes were (a) major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, or stroke and (b) any ischemic cardiovascular events (iCVE) including MACE, angina, revascularization, transient ischemic attack, and peripheral arterial disease. The effects of sex, prevalent methotrexate use at enrollment visit and their interaction on MACE and iCVE were assessed with multivariable Cox regression models, reporting adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results There were 237 first MACE and 358 first iCVE. The sex by methotrexate interaction was significant for MACE (p = 0.005) and iCVE (p = 0.006), suggesting the effect of methotrexate use on cardiovascular risk differed among males and females. In males, methotrexate use associated with lower risk of MACE (HR 0.32, [95% CI 0.12–0.83]) and iCVE (HR 0.43 [95% CI 0.21–0.85]). In females, methotrexate use was not associated with MACE (p = 0.267) or iCVE (p = 0.407). In sensitivity analyses, models with inverse probability of treatment weighting and models additionally adjusting for inflammation yielded similar results. Conclusion Methotrexate use associated with cardiovascular benefit in males but not females with RA and the effect was independent of inflammation.Keywords
Funding Information
- Pfizer (68633259)
This publication has 49 references indexed in Scilit:
- Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk LesionsArthritis & Rheumatology, 2020
- Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid ArthritisArthritis & Rheumatology, 2019
- Methotraxate‐Loaded Hybrid Nanoconstructs Target Vascular Lesions and Inhibit Atherosclerosis Progression in ApoE−/− MiceAdvanced Healthcare Materials, 2017
- Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular EventsArthritis & Rheumatology, 2015
- Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristicsArthritis & Rheumatism, 2010
- No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: Results from two Swedish population‐based rheumatoid arthritis cohortsArthritis & Rheumatism, 2009
- Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP‐1 monocyte/macrophagesArthritis & Rheumatism, 2008
- Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factorsArthritis & Rheumatism, 2001
- Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritisArthritis & Rheumatism, 2000